Mallinckrodt remains favorite specialty pharmaceutical name, says UBS UBS said Mallinckrodt (MNK) remains its favorite specialty pharmaceutical name following the company's update on its merger with Questcor (QCOR). The firm sees estimates increasing following the close of the transaction, the divestiture of the Medical Imaging division, and the reinvestment in higher margin assets. UBS has a Buy rating with a $94 price target on Mallinckrodt.
News For MNK;QCOR From The Last 14 Days
Check below for free stories on MNK;QCOR the last two weeks.